I'm LongbridgeAI, I can summarize articles.Alto Neuroscience estimated its cash, equivalents, and restricted cash at $244.2 million as of June 30, 2026. The preliminary, unaudited figure notes that the final balance may differ materially. Additionally, the company signaled a clinical strategy shift, accelerating and expanding the development of ALTO-207, including an additional planned Phase 3 trial for monotherapy in treatment-resistant depression.
- Alto Neuroscience estimated cash, cash equivalents, restricted cash of about USD 244.2 million as of June 30, 2026. * Figure was preliminary, unaudited; final quarter-end balance could differ materially. * Clinical strategy shift signaled: acceleration, expansion of ALTO-207 development. * Additional planned Phase 3 trial of ALTO-207 monotherapy in treatment-resistant depression. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082875), on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here